Koff Pharma’s technology is based on observations Dr. Labelle has made over a prestigious 30+ year career in the drug discovery industry. Many small molecule new chemical entities (NCEs) have not been developed into commercial entities because they did not conform to a certain standard set of criteria universally adopted by the industry. In retrospect, it is clear that many of these compounds could have been developed if the right tests and data interpretations had been applied. Koff Pharma seeks to prove that it is possible to design, prepare and test new molecules that can be developed into superior small molecule enzyme inhibitors more rapidly than with conventional methods using its kinetics-based technology. The Company has chosen to start this demonstration by designing inhibitors of two serine proteases implicated in diseases with high mortality toll. After the proof of concept has been established, many application fields will be open for this technology platform. Any use requiring permanent inhibition of an enzyme or modulation of an allosteric interaction is a potential application of Koff Pharma’s technology.